Reversible Intrapulmonary Vascular Dilatation in a Patient Treated With Luspatercept for Myelodysplastic Syndrome.

Fatema Al Lawati, Samir Gupta, Marie E Faughnan, John Granton, Troy Climans, Amar Thakrar, Geneviève C Digby

Abstract readCase Reports

In one paragraph

Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatema Al LawatiDivision of Respirology and Sleep Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada.

Samir GuptaDivision of Respirology, Department of Medicine, Li Ka Shing Knowledge Institute and St. Michael's Hospital, Toronto, ON, Canada.

Marie E FaughnanDivision of Respirology, Department of Medicine, Li Ka Shing Knowledge Institute and St. Michael's Hospital, Toronto, ON, Canada.

John GrantonDivision of Respirology, Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.

Troy ClimansDivision of Hematology, Department of Medicine Queen's University, Queen's University, Kingston, ON, Canada.

Amar ThakrarDivision of Cardiology, Department of Medicine, Queen's University, Kingston, ON, Canada.

Geneviève C DigbyDivision of Respirology and Sleep Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada. Electronic address: gcd1@queensu.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 70-year-old man with transfusion-dependent myelodysplastic syndrome was treated with luspatercept. Nine months into treatment and 2 months after dose increase, he developed new hypoxemia with a room air resting oxygen saturation of 88%. He was admitted, requiring up to 90% Fio

Indexed as

Activin Receptors, Type IIHematinicsHypoxiaMyelodysplastic SyndromesRecombinant Fusion ProteinsAgedDilatation, PathologicHumansImmunoglobulin Fc FragmentsMaleTomography, X-Ray ComputedActivin Receptors, Type IIHematinicsImmunoglobulin Fc FragmentsluspaterceptRecombinant Fusion Proteinsextrapulmonary shuntintrapulmonary vascular dilatationsluspatercept

Identifiers

PMID42575657

DOI10.1016/j.chest.2026.02.012

PMCPMC13494422

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.